Searchable abstracts of presentations at key conferences on calcified tissues

ba0003ht5 | (1) | ECTS2014

Skin inflammation causes bone loss with reduced bone formation through systemic IL-17A release

Uluckan Ozge , Keller Johannes , Karbach Susanne , Croxford Andrew , Finzel Stephanie , Koenders Marije , Berg Wim Van Den , Amling Michael , Waisman Ari , Schett Georg , Wagner Erwin

Patients with chronic inflammatory diseases such as psoriasis are at high risk for developing osteoporosis. Psoriatic arthritis patients exhibit bone loss caused by increased bone resorption through activation of osteoclasts. However, it is not clear whether psoriasis can lead to bone loss in the absence of arthritis. Using mouse models with skin inflammation as well as psoriasis patient samples, we show that increased circulating IL-17A from the inflamed skin triggers bone lo...

ba0003pp255 | Osteoporosis: evaluation and imaging | ECTS2014

Dynamic changes in bone marrow adiposity during the menstrual cycle

Veldhuis-Vlug Annegreet , Limonard Eelkje , van Dussen Laura , Runge Jurgen , Tanck Michael , Endert Erik , Heijboer Annemieke , Fliers Eric , Hollak Carla , Akkerman Erik , Bisschop Peter

Background: Bone marrow (BM) adiposity is inversely related to bone mineral density and increases with ageing and menopause. We previously observed that the variation in BM fat fraction was more pronounced in premenopausal women compared to men and postmenopausal women. We hypothesized that the variation in BM fat fraction in premenopausal women is associated with hormonal variations during the menstrual cycle.Objective: To investigate the dynamic change...

ba0003pp303 | Osteoporosis: treatment | ECTS2014

Gastrointestinal issues and osteoporosis treatment: the medication use patterns, treatment satisfaction, and inadequate control of osteoporosis study (MUSIC-OS)

Adachi Jonathan , Adami Silvano , Cortet Bernard , Cooper Alun , Geusens Piet , Mellstrom Dan , Modi Ankita , Sajjan Shiva , Sen Shuvayu , van den Bergh Joop

Objective: This multi-objective prospective observational study is intended to examine treatment patterns, occurrence of gastrointestinal (GI) complications and clinical and health outcomes in post-menopausal women with osteoporosis (OP) in Europe and Canada. This abstract presents the baseline results of the treated population.Materials and methods: Post-menopausal osteoporotic women currently on treatment completed surveys intended to measure the incid...

ba0003pp326 | Osteoporosis: treatment | ECTS2014

Undertreatment of osteoporosis: the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS)

Adachi Jonathan , Adami Silvano , Cortet Bernard , Cooper Alun , Geusens Piet , Mellstrom Dan , Modi Ankita , Sajjan Shiva , Sen Shuvayu , van den Bergh Joop

Objective: This multi-objective prospective study (MUSIC-OS) is intended to examine treatment patterns, occurrence of gastrointestinal (GI) complications and clinical and health outcomes in post-menopausal osteoporotic (OP) women in Europe and Canada. Surveys were administered to both physicians and patients as part of the MUSIC-OS study to document reasons for undertreatment in OP from both physician and patient perspectives.Materials and methods: A phy...

ba0004p71 | (1) | ICCBH2015

Muscle and bone impairment in children with Marfan syndrome: correlation with age and FBN1 genotype

Haine Elsa , Tauber Maithe , Van Kien Philippe Khau , Auriol Francoise , Gennero Isabelle , Julia Sophie , Dulac Yves , Salles Jean-Pierre , Edouard Thomas

Background: Marfan syndrome (MFS) is a rare connective tissue disorder caused by mutation in the gene encoding the extracellular matrix protein fibrillin-1 (FBN1), leading to transforming growth factor-beta (TGF-β) signaling dysregulation. Although decreased axial and peripheral bone mineral density (BMD) has been reported in adults with MFS, data about the evolution of bone mass during childhood and adolescence are limited.Objectives: The aim of th...

ba0001pp446 | Osteoporosis: treatment | ECTS2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate– a randomized placebo-controlled trial

Chapurlat Roland , De Villiers Tobias , Bonnick Sydney , Odio Alberto , Palacios Santiago , Scott Boyd , De Tilleghem Celine Le Bailly , DaSilva Carolyn , Leung Albert , Gurner Deborah

Odanacatib (ODN) is an orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN 50mg once weekly on BMD, bone turnover markers and safety in patients previously treated with alendronate (ALN).This was a randomized, double-blind, placebo-controlled, 24-month study. The primary endpoint was % change from baseline at month 24 of femoral neck (FN) BMD. Postmenopausal women (...

ba0002p102 | (1) | ICCBH2013

Influence of nutritional status in the bone mass assessed by quantitative ultrasonography of boys

de Oliveira Barbeta Vinicius Justino , Bertapelli Fabio , Goncalves Ezequiel Moreira , Krahenbuhl Tathyane , de Barros Ramalho Luiz Carlos , Martin Juan Eduardo Samur-San , Ribeiro Roberto Regis , Guerra-Junior Gil

The childhood is an important period for bone mass acquisition, and this tissue may be influenced by the nutritional status. However, the relation between the nutritional status and the bone parameters of quantitative ultrasound (QUS) remains unclear. The aim of this study was to verify the influence of nutritional status on bone mass assessed by QUS in male children from 7 to 10 years old. The sample consisted of 461 Brazilians pre-pubertal schoolchildren (8.30±1.13 year...

ba0005oc3.1 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Effect of odanacatib on bone density and estimated bone strength in postmenopausal women: a CT-based sub-study of the phase 3 long-term odanacatib fracture trial (LOFT)

Langdahl Bente , De Villiers Tobias , Keaveny Tony M , Engelke Klaus , Genant Harry , Ather Shabana , Giezek Hilde , Lombardi Antonio , Leung Albert , de Papp Anne

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk. This imaging sub-study primarily investigated the effect of ODN on volumetric BMD (vBMD) of the lumbar spine (LS) and total hip (TH) using quantitative computed tomography (QCT).Women aged ≥65 without baseline radiographic vertebra...